Navigation Links
Positive Results Prompt US National Cancer Institute to Make,Gleevec Available To Patients in Post-Surgical Gist Study

to moderate adverse events so that the prescribed dose can be maintained whenever possible. However, in some cases, either a dose reduction or interruption of treatment with Gleevec may be necessary

Gleevec tablets should be taken with food and a large glass of water to minimize GI irritation. Gleevec tablets should not be taken with grapefruit juice

Disclaimer

The foregoing release contains forward-looking statements that can be identified by terminology such as "will," "planned," or similar expressions, or by express or implied discussions regarding potential future regulatory submissions, new indications or new labeling for Gleevec, the long-term impact of a patient's use of Gleevec or potential future sales of Gleevec. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that additional regulatory submissions will be made in any particular jurisdictions, or that Gleevec will be approved for any additional indications or labeling in any market. Nor can there be guarantee regarding the long-term impact of a patient's use of Gleevec. Neither can there be any guarantee regarding potential future sales of Gleevec. In particular, management's expectations regarding Gleevec could be affected by, among other things, unexpected clinical trial results, including additional analysis of Gleevec clinical data, and new clinical data; unexpected regulatory actions or delays or government regulation generally; the company's ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and other risks and factors referred to in the Company's current Form 20-F on file with the US Securities and Exchange Commission. Should one or
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
2. Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Protox Announces Positive Clinical Data from Prostate Cancer Study
5. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
6. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
7. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
8. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Chi-Med Announces Positive Phase II Proof-of-Concept Data for HMPL-004 in Ulcerative Colitis
Post Your Comments:
(Date:8/3/2015)... SOUTH SAN FRANCISCO, Calif. , Aug. 3, ... therapeutics for the treatment of cancer, today announced ... team. Debanjan Ray , who ... and alliance management, has been promoted to senior ... to joining CytomX, Mr. Ray held positions as ...
(Date:8/3/2015)... FLORHAM PARK, N.J. , Aug. 3, ... met its primary and secondary endpoints in a phase ... constipation (OIC) in adult patients with chronic non-cancer pain. ... antagonist (PAMORA). This is the third Phase III trial ... endpoints. Study results showed that a 0.2 ...
(Date:8/3/2015)... (PK:ECIA), a medical device company owning patented surgical technology ... surgery, today announced financial results for its fiscal 2016 ... The Company posted quarterly net revenue of $2.454 million ... $(0.02) per share. These results compare to net revenue ... thousand, or $(0.02) per share, in the year-ago quarter. ...
Breaking Medicine Technology:CytomX Announces Management Team Promotions 2CytomX Announces Management Team Promotions 3Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 2Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 3Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 4Encision Reports First Quarter Fiscal Year 2016 Results 2Encision Reports First Quarter Fiscal Year 2016 Results 3Encision Reports First Quarter Fiscal Year 2016 Results 4Encision Reports First Quarter Fiscal Year 2016 Results 5
... 15 Watermark Medical , Inc., a privately-held, ... market, has expanded the market reach of its Web-enabled ... three leading sleep solution providers in the U.S. and ... national provider of comprehensive sleep apnea services; Sleep ...
... Vista Partners announced today that it has updated ... Principal Analyst at Vista Partners stated, "Raptor is potentially ... a balanced pipeline of clinical and preclinical programs.  The ... programs and one Phase 3 trial with some indications ...
Cached Medicine Technology:Three Leading Sleep Solution Providers Choose Watermark Medical's Web-Enabled Home Sleep Testing Solutions 2Three Leading Sleep Solution Providers Choose Watermark Medical's Web-Enabled Home Sleep Testing Solutions 3Three Leading Sleep Solution Providers Choose Watermark Medical's Web-Enabled Home Sleep Testing Solutions 4
(Date:8/3/2015)... (PRWEB) , ... August 03, 2015 , ... ... date of its industry-defining contract lifecycle management solution, as well as announced the ... to increase the speed and ease of contract management tasks as well as ...
(Date:8/3/2015)... Alachua, FL (PRWEB) , ... August 03, 2015 , ... ... peripheral nerve injuries, is scheduled to present at the Wedbush Healthcare Conference on Wednesday, ... , A live webcast and subsequent archived replay of the Company’s presentation may be ...
(Date:8/3/2015)... ... August 03, 2015 , ... The U.S. Food and Drug Administration (FDA) ... similar to deoxycholic acid, which occurs naturally in the body and helps absorb and ... this area of the body. These are invasive procedures and very expensive for most ...
(Date:8/3/2015)... ... August 03, 2015 , ... From 2006-2017 the number of ... to market research compiled for the National Association of Dental Laboratories ( NADL ... Bureau of Labor Statistics. As the number of dental laboratories decreases, dentists will ...
(Date:8/3/2015)... Ramon, CA (PRWEB) , ... August 03, 2015 ... ... leading global insurance brokerage firm, announced today that Joe Williams has joined its ... development, sales, and delivering HUB's differentiated service model to his clients. Mr. Williams ...
Breaking Medicine News(10 mins):Health News:Novatus Unveils Milestone Software Release 2Health News:AxoGen, Inc. to Present at the Wedbush Healthcare Conference 2Health News:Dr. Ava Shamban to Offer the New Double Chin Treatment Kybella 2Health News:Dr. Ava Shamban to Offer the New Double Chin Treatment Kybella 3Health News:Dental Association Announces Impending Reduction of Dental Laboratories Could Impact Dentists 2Health News:Dental Association Announces Impending Reduction of Dental Laboratories Could Impact Dentists 3Health News:HUB International Insurance Services Announces Joe Williams Has Joined its Northern California Employee Benefits Division 2
... CITY)Research into how carbohydrates are converted into energy has ... treatment of a perplexing and potentially fatal neuromuscular disorder ... this study, the cause of this neuromuscular disorder was ... members who have the disorder, a team led by ...
... , THURSDAY, May 24 (HealthDay News) -- While fewer people ... of strokes has remained about the same, health officials report. ... nation,s so-called "stroke belt." According to the report on ... strokes dipped slightly from 2.7 percent to 2.6 percent during ...
... a new, higher-yield, two-step, less costly process that may ... material essential for making the mainstay drug for malaria. ... more than 1 million. The report on the process, ... implemented by drug companies, appears in ACS, journal ...
... most comprehensive analyses to date of the cost of robotic-assisted, ... this now-dominant surgical approach is significantly more costly than standard ... outcomes. The results of the study are available online and ... Urology . In one of the first studies ...
... The British Association for Psychopharmacology (BAP) has released ... abuse and addiction in the Journal of Psychopharmacology ... carefully researched the new, comprehensive guidelines, offering practitioners a ... their clinical decisions. The new BAP guidelines target ...
... May 22 (HealthDay News) -- New research suggests that ... anticholinergics -- such as ipratropium [Atrovent] -- could be ... irregular heartbeat. However, the increased risk was ... this finding raises concern because of the recent interest ...
Cached Medicine News:Health News:Pivotal role for proteins -- from helping turn carbs into energy to causing devastating disease 2Health News:Strokes More Common in Southern States: CDC 2Health News:Robotic-assisted prostate cancer surgery drives up costs, UPMC study finds 2Health News:Robotic-assisted prostate cancer surgery drives up costs, UPMC study finds 3Health News:British experts update addiction treatment guidelines 2Health News:Asthma Meds May Be Linked to Irregular Heartbeat 2
... Markers have a unique squeezable barrel ... writing over wet prep solutions. Micro ... with optional rulers and sterile labels ... sterile, packaged individually in peel pouches. ...
Broad tip, gentian violet, sterile, disposable...
... The Surgifoam* absorbable gelatin sponge, U.S.P. ... gelatin absorbable sponge intended for hemostatic ... surface. The sponge is off-white and ... speed to hemostasis, highly favorable surgeon ...
9 mm diameter pigtail curved blunt probes. Stainless steel. Round knurled handle with polished finish. Includes pre-cut polyethylene tubes. Overall length: 5.9 inches....
Medicine Products: